Company Encyclopedia
View More
name
China Universal NASDAQ Biotechnology Technology ETF(QDII)
513290.SH
News
View More

A Closer Look at Insmed's Options Market Dynamics

High-rolling investors show bearish sentiment on Insmed (NASDAQ:INSM), with 75% bearish and 12% bullish options trades. Benzinga's scanner identified 8 trades, focusing on a price range of $32.5 to $200.0. Insmed's stock is up 1.45% at $180.0, with analysts maintaining positive ratings and target prices between $195 and $230. Options trading is riskier but offers higher profit potential. Benzinga Pro provides real-time alerts for Insmed's options trades.

benzinga_article·
US
INSM
+0.26%
benzinga_article·
US
INSM
+0.26%

Amgen Inc. $AMGN Stake Reduced by Pacer Advisors Inc.

Pacer Advisors Inc. reduced its stake in Amgen Inc. by 8.8% in Q3, now holding 1,613,121 shares. Amgen represents 1.1% of Pacer's portfolio. Other firms adjusted their Amgen holdings in Q2. Insiders sold 10,908 shares worth $3.67 million. Analysts have mixed ratings on Amgen, with a consensus "Moderate Buy" and a price target of $332.85. Amgen's stock opened at $332.50.

Market Beat·
US
AMGN
-0.31%
Market Beat·
US
AMGN
-0.31%

Exchange Traded Concepts LLC Purchases 1,369 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Exchange Traded Concepts LLC increased its stake in Regeneron Pharmaceuticals by 34.7% in Q3, owning 5,309 shares valued at $2,985,000. Analysts have mixed ratings, with a consensus "Moderate Buy" and a price target of $779.45. Regeneron reported Q3 earnings of $11.83 per share, beating estimates, with revenue of $3.75 billion. The company announced a quarterly dividend of $0.88 per share.

Market Beat·
US
REGN
+0.16%
Market Beat·
US
REGN
+0.16%

Gilead Sciences to acquire Repare’s RP-3467

Gilead Sciences has agreed to acquire Repare Therapeutics' Polθ ATPase inhibitor, RP-3467, for up to $30 million. The deal includes a $25 million upfront payment and up to $5 million upon technology transfer completion. This acquisition boosts Repare's cash reserves, impacting shareholder payments, estimated at $2.20 per share. Repare's CEO, Steve Forte, highlights the transaction as a significant portfolio move, combining Gilead's oncology expertise with RP-3467's potential in targeting BRCA mutations.

Pharmaceutical Technology·
US
RPTX
+0.78%
US
GILD
-0.77%
Pharmaceutical Technology·
US
RPTX
+0.78%
US
GILD
-0.77%

Does FDA’s UPLIZNA gMG Expansion Reshape the Bull Case for Amgen’s Diversification Story (AMGN)?

The FDA's approval of Amgen's UPLIZNA for generalized myasthenia gravis expands its autoimmune portfolio, reinforcing its diversification strategy. This approval, alongside IMDELLTRA for lung cancer, highlights Amgen's efforts to offset maturing products with new therapies. However, biosimilar competition and pricing pressures remain significant challenges. Analysts have mixed views on the impact of UPLIZNA's approval on Amgen's revenue and earnings forecasts. The company's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, with a fair value estimate of $322.88 per share.

Simplywall·
US
AMGN
-0.31%
Simplywall·
US
AMGN
-0.31%
© 2025 Longbridge｜Disclaimer